SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that, in connection with the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development, Erasca’s Board of Directors has approved the grant of inducement awards.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
